Clinical trials: Dermatomyositis, Adult Type
Dermatomyositis, Polymyositis
Methimazole to Treat Polymyositis and Dermatomyositis
This study will test the safety and effectiveness of the drug methimazole in treating polymyositis and dermatomyositis-inflammatory muscle diseases causing weakness and muscle wasting.
- Trial name
- NCT00001421
- Testing
- methimazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Trial name
- NCT07089121
- Testing
- Descartes-08
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cartesian Therapeutics
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Myositis, Dermatomyositis
Environmental Risk Factors for the Anti-synthetase Syndrome
Background: Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors.
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
- Trial name
- NCT01276470
- Where
- 8 sites in United States
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)
FT839 in Autoimmune Diseases
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or…
- Conditions
- ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07800871
- Testing
- FT839
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Fate Therapeutics
Dermatomyositis, Adult Type
The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
Anti-melanoma differentiation-associated gene5 (Anti-MDA5) antibody positive Dermatomyositis (DM) is a subtype of DM that is more frequent in East Asia, which is often exhibit skin lesion, clinically amyopathic and interstitial…
- Trial name
- NCT04966884
- Testing
- JAK Inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Dermatomyositis, Adult Type
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.
- Trial name
- NCT05986162
- Testing
- Itolizumab
- Volunteers
- 44 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Autoimmune/Connective Tissue Diseases, Idiopathic Inflammatory Myopathies
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
This study will define the major genetic risk and protective factors for idiopathic inflammatory myopathies (IIM), a group of immune disorders affecting connective tissues such as muscles.
- Conditions
- Autoimmune/Connective Tissue Diseases, Idiopathic Inflammatory Myopathies, Polymyositis, Dermatomyositis
- Trial name
- NCT00341679
- Where
- United States
- Volunteers
- 719 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Myositis, Juvenile
Exercise, Creatine and Coenzyme Q10 for Childhood Myositis
Children with Juvenile Idiopathic Inflammatory Myopathies (JIIM) are weak and get tired because their muscles aren't able to work like healthy muscles.
- Trial name
- NCT04286178
- Testing
- creatine monohydrate, ubiquinol, glucose tablet
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- The Hospital for Sick Children
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Dermatomyositis
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
This study will evaluate the safety and effectiveness of the experimental drug h5G1.1-mAb in treating patients with dermatomyositis.
- Trial name
- NCT00005571
- Testing
- h5G1.1-mAb
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Polymyositis, Dermatomyositis
Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
This randomized, double-blind, placebo-controlled trial will carry out to assess the efficacy of GB-0998 in the treatment of the steroid-resistant polymyositis and dermatomyositis based on the changes in manual muscle strength…
- Trial name
- NCT00335985
- Testing
- GB-0998
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Japan Blood Products Organization
Dermatomyositis (DM), ILD
Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters
The investigators investigated the associations between the imaging parameters of ⁶⁸Ga-FAPI and ¹⁸F-FDG dual-tracer PET/CT and concomitant interstitial lung disease (ILD) in patients with dermatomyositis (DM), developed a novel…
- Conditions
- Dermatomyositis (DM), ILD, Machine Learning, Radiomics
- Trial name
- NCT07531446
- Testing
- Observe the medical images, Extracting image feature
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Myositis, Polymyositis
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Idiopathic inflammatory myopathies (IIM) are a great concern in acquired muscle illnesses. An appropriate and rapid diagnosis is necessary, because morbidity and mortality are high and a specific treatment is needed.
- Conditions
- Myositis, Polymyositis, Dermatomyositis, Myositis, Inclusion Body
- Trial name
- DARWIM (NCT01432613)
- Testing
- MRI-oriented muscle biopsy
- Where
- France
- Volunteers
- 139 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dermatomyositis
Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS
- Trial name
- NCT03686969
- Testing
- Octanorm
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Octapharma
Inflammatory Myopathy, Idiopathic, Dermatomyositis
Add-on Intravenous Immunoglobulins in Early Myositis
In patients with myositis early immunomodulation by intensive treatment ("hit-early/hit-hard" principle) may induce faster reduction of disease activity and prevent chronic disability.
- Conditions
- Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome, Immune-Mediated Necrotizing Myopathy
- Trial name
- TIMEISMUSCLE (NCT05832034)
- Testing
- Immune Globulin Intravenous (Human)
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Dermatomyositis, Polymyositis
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis…
- Trial name
- NCT01906372
- Testing
- Adrenocorticotropic Hormone Gel
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Rohit Aggarwal, MD
Dermatomyositis, Abatacept
An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis
Dermatomyositis is a heterogeneous disease characterized by involvement of the proximal muscles of the extremities. Some patients have treatment failure or intolerance to the above treatment regimens, which is called refractory…
- Trial name
- NCT04946669
- Testing
- Abatacept
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Dermatomyositis Interstitial Lung Disease (Dm-ILD)
Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease
- Trial name
- NCT03857854
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Dermatomyositis
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children.
- Trial name
- JADE (NCT06004817)
- Testing
- evaluation of clinical severity
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France